**Core tip:** As a proof-of-concept of the advantages that can be yielded by applying multi-omics systems-based approaches to the analysis of potential candidates to the treatment of nonalcoholic steatohepatitis (NASH) we selected the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway map of nonalcoholic fatty liver disease (NAFLD), which illustrates a stage-dependent progression of the disease. After generating a protein−chemical interaction network, we predicted remarkable examples of potential drug repurposing for the treatment of NASH based on the NAFLD-KEGG connectivity map.

INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has emerged as the leading global cause of chronic liver damage in recent years\[[@B1]\]. The disease course progresses through highly dynamic histological stages, ranging from simple steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), NASH-fibrosis and cirrhosis\[[@B1],[@B2]\]. NASH-fibrosis and its complications, including cirrhosis and hepatocellular carcinoma, not only significantly reduce life expectancy by increasing liver-related mortality\[[@B3]\] but also represent a challenge for the healthcare system because much of the affected population is also affected by NAFLD-associated comorbidities, including obesity, type 2 diabetes (T2D), and cardiovascular disease\[[@B1],[@B4]-[@B6]\]. Absence of reliable noninvasive biomarkers that allow identification of patients at a high risk of fibrosis and /or disease progression is one of the obstacles facing disease management\[[@B7],[@B8]\]. Similarly, while a large number of drugs against NASH are currently being tested for efficacy and safety, no pharmacological interventions are presently approved for treating NASH\[[@B2],[@B5],[@B9],[@B10]\].

Information retrieved from public domain data sources and clinical ClinicalTrials.gov (updated December 2018), a resource provided by the U.S. National Library of Medicine, indicates that approximately 47 different drugs that target NASH and NASH-fibrosis are currently being tested in different pharmacological stages, including 188 drugs in phase 1 and 162 in phase 2 studies (Figure [1](#F1){ref-type="fig"}). A significant proportion of these drugs are small molecules or proteins that either antagonize or act as exogenous agonists of one or more targets of interest; the 47 aforementioned NASH drugs are in fact predicted to be linked to 151 molecular targets (Figure [1](#F1){ref-type="fig"}). Considering that a large majority of these drugs are in the earliest pharmacological phases that involve testing tolerability, therapeutic action, and pharmacological issues, it is reasonable to conclude that there will be a significant time lag before the next generation of NASH drugs is available for clinical use.

![Clinical trials for the treatment of nonalcoholic steatohepatitis. A and B: Figure highlights 47 drugs that are currently under investigation for the treatment of nonalcoholic steatohepatitis in different pharmacological phases (from phase 1 to phase 4): Information on clinical trial status (recruitment status) as well as prediction of potential associated targets were retrieved from the Target Validation Platform available at https://[www.targetvalidation.org](www.targetvalidation.org); C: Drugs listed in the most advanced pharmacological phase updated December 2018 concerning to privately and publicly funded clinical studies. Not yet recruiting: The study has not started recruiting participants; Recruiting: The study is currently recruiting participants; Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled; Terminated: The study has stopped early and will not start again; participants are no longer being examined or treated; Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant\'s last visit has occurred); Withdrawn: The study stopped early, before enrolling its first participant; Unknown: A study on ClinicalTrials.gov whose last known status was recruiting; not yet recruiting; or active, not recruiting but that has passed its completion date, and the status has not been last verified within the past 2 years).](WJG-25-1783-g001){#F1}

One potential solution to this expected delay is drug repurposing or repositioning, which relies on identifying and developing new uses for existing drugs\[[@B11]\]. The advantage of drug repurposing is not limited to the fact that drugs selected for a novel indication have already passed the time-consuming pharmacokinetics, pharmacodynamics, and toxicity profiling evaluation, but are also already approved by major regulatory agencies, including the United States Food and Drug Administration and/or the European Medicines Agency.

Drug repurposing can be addressed by different approaches. Most common ones involve the selection of drug candidate/s based on known targets involved in the pathogenesis of the disease of interest. More recently, system biology strategies based on a broad search into genomic resources, as well as large-scale gene expression libraries, have been proposed as an attractive and innovative solution, particularly for the treatment of complex diseases like NAFLD that shares disease mechanisms with diseases of the metabolic syndrome\[[@B12]-[@B14]\]. Hence, we propose a drug candidate selection method based on the integration of molecular pathways of disease pathogenesis into network analysis tools that use OMICs data as well as multiples sources, including text mining from pertinent medical literature.

including text mining from pertinent medical literature

including text mining from pertinent medical literature

DRUG REPURPOSING FOR THE TREATMENT OF NASH BASED ON THE NAFLD-KEGG CONNECTIVITY MAP
===================================================================================

As a proof-of-concept of the advantages of using multi-omics systems-based approaches for the analysis of potential NASH treatment candidates, we selected the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway map of NAFLD (pathway ID: hsa04932), which illustrates a stage-dependent progression of the disease (Figure [2](#F2){ref-type="fig"}). This pathway is composed of 149 genes/proteins involved not only in the progression of NAFL to NASH and to cirrhosis, but also genes/proteins shared with obesity and T2D (Table [1](#T1){ref-type="table"}). Significant disease-related pathogenic processes, including *de novo* fatty acid biosynthesis, lipid peroxidation, endoplasmic reticulum stress and mitochondrial dysfunction\[[@B15]-[@B17]\], as well as apoptosis and cell death related mechanisms are represented in the NAFLD-KEGG pathway (Figure [2](#F2){ref-type="fig"}). Thus, we generated a protein−chemical interaction network by mapping the significant genes/proteins that are represented in the pathway to chemicals/drugs that are annotated in the Comparative Toxicogenomics Database. The 149 genes (seeds) yielded by our analysis were then mapped to the corresponding molecular interaction database; this procedure produced an extensive network comprising of approximately 2000 nodes. One of the largest subnetworks included 3212 smaller nodes (that represent the number of gene/protein--chemical interactions in this subnetwork), with 13314 interactions among node members. For simplicity, we manually curated some chemical−drug interactions focusing specifically on certain genes/proteins of potential interest, including members of the caspase family (CASP3 and CASP7), interleukins (IL1A, IL1B, and IL6), tumor necrosis factor α (TNFα), nuclear factor kappa B subunit 1 (NFKB1) and inhibitor of nuclear factor kappa B kinase subunit beta, Jun proto-oncogene (JUN), transcription factor subunit, and AKT serine/threonine kinase 1 (Figure [3](#F3){ref-type="fig"}). Remarkably, several drugs were predicted to have a significant interaction with the highlighted targets. For example, minocycline that is a broad spectrum long-acting derivative of the antibiotic tetracycline was mapped in the pathway of caspases, whereas IL1B (Figure [3](#F3){ref-type="fig"}) or pomalidomide that is a derivative of thalidomide with immuno-modulating, antiangiogenic and antineoplastic activities was mapped in the network of TNF, NFKB1, and interleukins (Figure [3](#F3){ref-type="fig"}).

###### 

Non-alcoholic fatty liver disease-Kyoto Encyclopedia of Genes and Genomes pathway (hsa04932)

  **Gene symbol; description**
  --------------------------------------------------------------------------------
  IL6; interleukin 6
  IL6R; interleukin 6 receptor
  SOCS3; suppressor of cytokine signaling 3
  TNF; tumor necrosis factor
  TNFRSF1A; TNF receptor superfamily member 1A
  NFKB1; nuclear factor kappa B subunit 1
  RELA; RELA proto-oncogene, NF-kB subunit
  INS; insulin
  INSR; insulin receptor
  IRS1; insulin receptor substrate 1
  IRS2; insulin receptor substrate 2
  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1
  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2
  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3
  AKT1; AKT serine/threonine kinase 1
  AKT2; AKT serine/threonine kinase 2
  AKT3; AKT serine/threonine kinase 3
  GSK3A; glycogen synthase kinase 3 alpha
  GSK3B; glycogen synthase kinase 3 beta
  NR1H3; nuclear receptor subfamily 1 group H member 3
  RXRA; retinoid X receptor alpha
  SREBF1; sterol regulatory element binding transcription factor 1
  MLX; MLX, MAX dimerization protein
  MLXIP; MLX interacting protein
  MLXIPL; MLX interacting protein like
  PKLR; pyruvate kinase L/R
  LEP; leptin
  LEPR; leptin receptor
  ADIPOQ; adiponectin, C1Q and collagen domain containing
  ADIPOR1; adiponectin receptor 1
  ADIPOR2; adiponectin receptor 2
  PRKAA1; protein kinase AMP-activated catalytic subunit alpha 1
  PRKAA2; protein kinase AMP-activated catalytic subunit alpha 2
  PRKAB1; protein kinase AMP-activated non-catalytic subunit beta 1
  PRKAB2; protein kinase AMP-activated non-catalytic subunit beta 2
  PRKAG1; protein kinase AMP-activated non-catalytic subunit gamma 1
  PRKAG3; protein kinase AMP-activated non-catalytic subunit gamma 3
  PRKAG2; protein kinase AMP-activated non-catalytic subunit gamma 2
  PPARA; peroxisome proliferator activated receptor alpha
  CDC42; cell division cycle 42
  RAC1; Rac family small GTPase 1
  MAP3K11; mitogen-activated protein kinase kinase kinase 11
  MAPK8; mitogen-activated protein kinase 8
  MAPK10; mitogen-activated protein kinase 10
  MAPK9; mitogen-activated protein kinase 9
  ITCH; itchy E3 ubiquitin protein ligase
  ERN1; endoplasmic reticulum to nucleus signaling 1
  TRAF2; TNF receptor associated factor 2
  MAP3K5; mitogen-activated protein kinase kinase kinase 5
  JUN; Jun proto-oncogene, AP-1 transcription factor subunit
  IL1A; interleukin 1 alpha
  IL1B; interleukin 1 beta
  IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta
  XBP1; X-box binding protein 1
  CEBPA; CCAAT enhancer binding protein alpha
  CYP2E1; cytochrome P450 family 2 subfamily E member 1
  FASLG; Fas ligand
  CXCL8; C-X-C motif chemokine ligand 8
  TGFB1; transforming growth factor beta 1
  EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3
  EIF2S1; eukaryotic translation initiation factor 2 subunit alpha
  ATF4; activating transcription factor 4
  DDIT3; DNA damage inducible transcript 3
  BCL2L11; BCL2 like 11
  BAX; BCL2 associated X, apoptosis regulator
  FAS; Fas cell surface death receptor
  CASP8; caspase 8
  BID; BH3 interacting domain death agonist
  CYCS; cytochrome c, somatic
  CASP3; caspase 3
  CASP7; caspase 7
  NDUFV1-3; NADH:ubiquinone oxidoreductase core subunit V1 --V3
  NDUFA1-3; NADH:ubiquinone oxidoreductase subunit A1-3
  NDUFA4; NDUFA4, mitochondrial complex associated
  NDUFA4L2; NDUFA4, mitochondrial complex associated like 2
  NDUFA5-13; NADH:ubiquinone oxidoreductase subunit A5-A13
  NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1
  NDUFB1-11; NADH:ubiquinone oxidoreductase subunit B1-B11
  NDUFS1-S8; NADH:ubiquinone oxidoreductase core subunit S1 --S8
  NDUFC1; NADH:ubiquinone oxidoreductase subunit C1
  NDUFC2; NADH:ubiquinone oxidoreductase subunit C2
  NDUFC2-KCTD14; NDUFC2-KCTD14 readthrough
  SDHA; succinate dehydrogenase complex flavoprotein subunit A
  SDHB; succinate dehydrogenase complex iron sulfur subunit B
  SDHC; succinate dehydrogenase complex subunit C
  SDHD; succinate dehydrogenase complex subunit D
  UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
  CYTB; cytochrome b
  CYC1; cytochrome c1
  UQCRC1; ubiquinol-cytochrome c reductase core protein 1
  UQCRC2; ubiquinol-cytochrome c reductase core protein 2
  UQCRH; ubiquinol-cytochrome c reductase hinge protein
  UQCRHL; ubiquinol-cytochrome c reductase hinge protein like
  UQCRB; ubiquinol-cytochrome c reductase binding protein
  UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII
  UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X
  UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI
  COX3; cytochrome c oxidase III
  COX1; cytochrome c oxidase subunit I
  COX2; cytochrome c oxidase subunit II
  COX4I2; cytochrome c oxidase subunit 4I2
  COX4I1; cytochrome c oxidase subunit 4I1
  COX5A; cytochrome c oxidase subunit 5A
  COX5B; cytochrome c oxidase subunit 5B
  COX6A1; cytochrome c oxidase subunit 6A1
  COX6A2; cytochrome c oxidase subunit 6A2
  COX6B1; cytochrome c oxidase subunit 6B1
  COX6B2; cytochrome c oxidase subunit 6B2
  COX6C; cytochrome c oxidase subunit 6C
  COX7A1; cytochrome c oxidase subunit 7A1
  COX7A2; cytochrome c oxidase subunit 7A2
  COX7A2L; cytochrome c oxidase subunit 7A2 like
  COX7B; cytochrome c oxidase subunit 7B
  COX7B2; cytochrome c oxidase subunit 7B2
  COX7C; cytochrome c oxidase subunit 7C
  COX8C; cytochrome c oxidase subunit 8C
  COX8A; cytochrome c oxidase subunit 8A

https://[www.genome.jp/kegg-bin/show_pathway?](www.genome.jp/kegg-bin/show_pathway?) hsa04932.

![Nonalcoholic fatty liver disease-Kyoto Encyclopedia of Genes and Genomes pathway and mechanisms of disease pathogenesis. Pathway was retrieved from https://[www.genome.jp/dbget-bin/www_bget?pathway+hsa04932](www.genome.jp/dbget-bin/www_bget?pathway+hsa04932); figure was modified to highlight key molecular processes. This map shows a stage-dependent progression of nonalcoholic fatty liver disease (NAFLD). In the first stage of NAFLD, pathway highlights excess lipid accumulation associated with the induction of insulin resistance, which leads to a defect in insulin suppression of free fatty acids (FAAs) disposal. In addition, two transcription factors, SREBP-1c and PPARα, activate key enzymes of lipogenesis and increase the synthesis of FAAs in liver. In the second stage, pathway is presented as a consequence of the progression to nonalcoholic steatohepatitis (NASH); the production of reactive oxygen species is enhanced due to oxidation stress through mitochondrial beta-oxidation of fatty acids and endoplasmic reticulum (ER) stress, leading to lipid peroxidation. The lipid peroxidation can further cause the production of cytokines \[Fas ligand, tumor necrosis factor α (TNF-α), IL-8 and transforming growth factor\], promoting cell death, inflammation and fibrosis. The activation of JNK, which is induced by ER stress, TNF-α and FAAs, is also associated with NAFLD progression. Increased JNK promotes cytokine production and initiation of hepatocellular carcinoma. Major organelles involved in the pathogenesis of NASH are also highlighted in the NAFLD-pathway, including mitochondria and mitochondrial dysfunction. In the figure, molecular targets that were further selected to explore protein-chemical interactions are highlighted by red squares. NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; ER: Endoplasmic reticulum; HCC: Hepatocellular carcinoma; NAFL: Nonalcoholic fatty liver; FAAs: Free fatty acids; TNFα: tumor necrosis factor α.](WJG-25-1783-g002){#F2}

![Protein-chemical interactions and potential repurposing drugs to target nonalcoholic steatohepatitis. We generated a protein-chemical interaction network by mapping the significant genes/proteins that are represented in the nonalcoholic fatty liver disease-Kyoto Encyclopedia of Genes and Genomes pathway to chemicals/drugs that are annotated in the Comparative Toxicogenomics Database. The 149 genes (seeds) from our analysis were mapped to the corresponding molecular interaction database; full list of seed genes is listed in Table [1](#T1){ref-type="table"}. This analysis generated a huge network composed of approximately 2000 nodes. Current figure shows chemical-drug-interactions specifically focused on selected genes/proteins of potential interest, including members of the caspase family (CASP3 and CASP7), interleukins (IL1B, IL1A, and IL6), tumor necrosis factor α (TNF-α), NFKB1 (Nuclear factor kappa B subunit 1) and IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta), JUN (Jun proto-oncogene, AP-1 transcription factor subunit), AKT1 (AKT serine/threonine kinase 1). In green charts we summarized information on current use and known action of selected drugs. Interaction network was predicted by the Networkanalyst resource available at https://[www.networkanalyst.ca/faces/home.xhtml](www.networkanalyst.ca/faces/home.xhtml). The network is shown as a Cytoscape graph.](WJG-25-1783-g003){#F3}

Additional targets predicted in the minoclycline interaction network are arachidonate 5-lipoxygenase (which is involved in the synthesis of leukotrienes from arachidonic acid), cytochrome C (a central component of the electron transport chain in mitochondria), matrix metallopeptidase 9 (involved in the breakdown of extracellular matrix), vascular endothelial growth factor A (which induces proliferation and migration of vascular endothelial cells, particularly during pathological angiogenesis) and Poly(ADP-ribose) polymerase 1 (which is involved in the regulation of a myriad of cellular processes, such as differentiation, proliferation, and tumor transformation, as well as in the regulation of the molecular events implicit in the cell recovery from DNA damage). Further two candidate targets predicted in the network of pomalidomide are prostaglandin-endoperoxide synthase 2 (also known as cyclooxygenase, which is the key enzyme in prostaglandin biosynthesis) and CRBN (a calcium channel membrane protein, thought to play a role in brain development).

Additional examples of drugs that could be potentially tested for the treatment of NASH based on the concept of drug repositioning are illustrated in Figure [3](#F3){ref-type="fig"}. Drugs in the category of angiotensin II receptor type 1 (AGTR1) antagonists that were predicted in the network of JUN, for instance irbersartan-a nonpeptide AGTR1 antagonist with antihypertensive activity-might indeed be regarded as an indication expansion rather than drug repositioning because, as mentioned above, NAFLD and components of the Metabolic Syndrome, including arterial hypertension, present shared disease mechanisms (12-14). Therefore, given the pleiotropic effects of AGTR1 blockers\[[@B18]\] it is plausible to suggest that drugs in this pharmacological group-sartans-would synergize or potentiate the benefits of blocking the renin angiotensin system in the liver\[[@B19]-[@B22]\]. Remarkably, the pharmacological properties and toxicity profiles of some of the drugs presently undergoing NASH clinical trials are already known, such as atorvastatin, ezetimibe, fenofribrate, losartan, and pioglotazone, just to mention a few (Figure [1](#F1){ref-type="fig"}).

PLEIOTROPY: CHALLENGES AND OPPORTUNITIES FOR THE TREATMENT OF NASH
==================================================================

It is also important to acknowledge the possibility that some of the novel pharmacotherapy options for the treatment of NASH might eventually present pleiotropic effect/s. This point represents the paradox of a drug covering multiple pathways and cell types, which could be either harmful or beneficial for patients. Remarkable examples of the advantages of pleiotropic effects of pharmacological targets for the treatment of complex traits are, as already mentioned, agents that modulate or interfere with the rennin−angiotensin system, which not only reduce cardiovascular risk but also improve systemic inflammation, oxidative stress, and even present anti-fibrogenic properties in the liver. Similar effects have also been demonstrated for statins\[[@B23],[@B24]\].

When focusing on the new generation of NASH targets, obeticholic acid (OCA), a synthetically-modified bile acid (a dihydroxy-5beta-cholanic acid), is a remarkable example of the potential systemic effects of a drug targeting nuclear receptors. OCA exhibits a potent agonist effect on the farnesoid X nuclear receptor (FXR). More importantly, its target-FXR (formally Nuclear hormone receptor subfamily 1 group H member 4, NR1H4, also known as BAR) is predicted to be involved in the pathogenesis of multiple phenotypes that practically cover the full range of human diseases and traits (Figure [4](#F4){ref-type="fig"}). It is well known that OCA is currently used to treat not only NASH but other chronic liver diseases as well, including primary biliary cholangitis\[[@B25]\]. However, there are at least 65 registered clinical trials in various pharmacological phases for \~50 different diseases (Figure [4](#F4){ref-type="fig"}).

![Farnesoid X nuclear receptor (nuclear hormone receptor subfamily 1 group H member 4): Analysis of pleiotropy. A: Graph shows all predicted diseases associated with farnesoid X nuclear receptor; B: Clinical trials of drugs that target farnesoid X nuclear receptor. Predictions were explored in The Open Targets Platform that allows prioritisation of drug targets based on the strength of their association with a disease (https://[www.targetvalidation.org/](www.targetvalidation.org/)); C: Evidence curated from ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world. https://clinicaltrials.gov/. Diseases are presented as bubbles grouped into therapeutic areas using their Experimental Factor Ontology relationships. The size and shade of the color of each bubble is proportional to the strength of association between the disease and farnesoid X nuclear receptor. The concept of a target-disease association is based on the analysis of several resources, including genetic associations (GWAS Catalog, UniProt, European Variation Archive, Gene2Phenotype), somatic mutations (Cancer Gene Census, European Variation Archive somatic, IntOGen), RNA expression (expression atlas), drugs (ChEMBL), affected pathways (Reactome), animal models (PhenoDigm) and text mining (Europe PMC). The platform is available at https://[www.targetvalidation.org](www.targetvalidation.org). Data last updated December 2018.](WJG-25-1783-g004){#F4}

Based on this evidence, one may presume that the pleiotropic effects, and thus the clinical consequences, of the novel NASH drugs that are predicted to concurrently modulate a broad range of molecular pathways could be surprisingly extensive and therefore largely beneficial for treating multiple phenotypes. However, potential pleiotropic effects of the novel anti-NASH drugs could produce undesirable effects that we need to understand in order to anticipate their management. Some of these potential pleiotropic effects are indeed related to the primary biological and molecular network associated with the drug target itself. To illustrate the importance of this issue, we randomly selected five molecular targets (MAP3K5 or ASK1, FXR, PPARα/δ, THRβ, and MPC1) against which five drugs are currently being tested in patients with NASH (selonsertib\[[@B26]\], OCA\[[@B27]\], elafibranor\[[@B28]\], MGL-3196 (https://clinicaltrials.gov/ct2/show/NCT02912260), and MSDC-0602K\[[@B29]\] https://clinicaltrials.gov/ct2/show/NCT02784444). Next, we explored the potential pleiotropic effect/s of modulating these targets in humans by searching for associations of genetic variants in the aforementioned targets with different phenotypes and traits, known as PheWAS (Phenome-wide association studies). We specifically retrieved publically available information from the United Kindom Biobank that explored genetic variations in 452264 United Kindom Biobank White British individuals (<http://geneatlas.roslin.ed.ac.uk/>)\[[@B30]\].

As shown in Figure [5](#F5){ref-type="fig"} and Table [2](#T2){ref-type="table"}, *MAP3K5/ASK1*, *FXR*, *PPARα/δ*, *THRβ*, and *MPC1* variants are involved in multiple pleiotropic effects, including modulation of blood cell count, body mass index, and general body adiposity, along with complex systemic disorders, such as asthma, acute pancreatitis, migraine, intestinal malabsortium, thyroid disease, and malignant neoplasm. Hence, understanding the pleiotropic effects of the novel NASH drugs is the key to optimizing their use as well as preventing emergent-yet poorly understood-undesirable systemic complications that could potentially jeopardize their short- or long-term use.

###### 

Associations between variants in locus that are targets of novel drugs for the treatment of nonalcoholic steatohepatitis and multiple traits from individuals of the United Kindom Biobank

  **Trait**                                                                     **Variant**   **Position**   **-log10(p-value)**
  ----------------------------------------------------------------------------- ------------- -------------- ---------------------
  ***NR1H4 (FXR)* Farnesoid X-Activated Receptor**                                                           
  K85 Acute pancreatitis                                                        rs76372051    100945711      6.963890333
  Immature reticulocyte fraction                                                rs35712       100971355      5.607954097
  Impedance of arm (right)                                                      rs1409791     100851307      5.152661824
  Impedance of whole body                                                       rs1409791     100851307      4.772216099
  migraine                                                                      rs12579460    100966714      4.639293011
  high cholesterol                                                              rs7967468     100853792      4.543497322
  N30-N39 Other diseases of urinary system                                      rs79306023    100938470      4.420628035
  H81 Disorders of vestibular function                                          rs140644635   100923359      4.069764347
  *PPARδ* (**Peroxisome Proliferator Activated Receptor Delta)**                                             
  Whole body fat-free mass                                                      rs36018387    35386872       59.74853212
  Hip circumference                                                             rs36018387    35386872       49.20670564
  Whole body fat mass                                                           rs36018387    35386872       37.00113934
  Body fat percentage                                                           rs36018387    35386872       20.45328464
  Monocyte percentage                                                           rs9469982     35267548       45.86340625
  Platelet crit                                                                 rs33959228    35259397       21.6726615
  White blood cell (leukocyte) count                                            rs9380500     35266231       21.54556677
  Platelet count                                                                rs9658111     35364534       17.88276186
  Neutrophill count                                                             rs9380500     35266231       17.11253462
  Eosinophill percentage                                                        rs2395625     35405461       15.34904201
  Lymphocyte percentage                                                         rs9658079     35327577       9.741626151
  asthma                                                                        rs1557568     35260530       9.184130164
  K90 Intestinal malabsorption                                                  rs7771474     35320447       11.86097145
  *MPC1* (**Mitochondrial Pyruvate Carrier 1)**                                                              
  Mean platelet (thrombocyte) volume                                            rs10946160    166757818      7.378512135
  Platelet count                                                                rs3728        166778679      5.285527735
  Red blood cell (erythrocyte) count                                            rs6916128     166759313      4.825911105
  M31 Other necrotising vasculopathies                                          rs7449594     166774429      4.699926505
  dyspepsia / indigestion                                                       rs6909951     166758198      4.594790286
  *MAP3K5* (**ASK-1)** (**Mitogen-Activated Protein Kinase Kinase Kinase 5)**                                
  Mean platelet (thrombocyte) volume                                            rs6924387     137082948      14.48853109
  Eosinophill count                                                             rs932589      137083138      13.39556873
  Lymphocyte percentage                                                         rs6924387     137082948      10.84396601
  Neutrophill count                                                             rs6924387     137082948      10.59715422
  Platelet count                                                                rs9321570     137095679      9.792150289
  White blood cell (leukocyte) count                                            rs6924387     137082948      9.574319083
  Eosinophill percentage                                                        rs932589      137083138      9.344890391
  Monocyte count                                                                rs9385775     137144920      9.1157769
  Mean reticulocyte volume                                                      rs9385775     137144920      8.817927896
  Platelet distribution width                                                   rs6924387     137082948      8.001963098
  *THRβ* (**Thyroid Hormone Receptor Beta)**                                                                 
  Mean corpuscular volume                                                       rs869785      24347800       152.2743497
  Mean corpuscular haemoglobin                                                  rs869784      24348008       143.9371173
  Red blood cell (erythrocyte) count                                            rs869785      24347800       61.9076303
  Mean reticulocyte volume                                                      rs869784      24348008       43.97976306
  Reticulocyte count                                                            rs1505307     24343330       16.57632823
  Immature reticulocyte fraction                                                rs869784      24348008       15.67096843
  Monocyte count                                                                rs12485694    24346109       11.11788547
  Lymphocyte count                                                              rs13096529    24232035       10.58643203
  Red blood cell (erythrocyte) distribution width                               rs2167115     24339734       10.44361306
  C56 Malignant neoplasm of ovary                                               rs189397255   24389732       12.2277003
  Trunk fat-free mass                                                           rs13100197    24491484       8.731024419
  Trunk predicted mass                                                          rs13100197    24491484       8.614769205
  Leg fat percentage (left)                                                     rs1349265     24159387       8.323233252

The associations have been computed using 452264 United Kindom Biobank White British individuals. <http://geneatlas.roslin.ed.ac.uk/>.

![The complexity of molecular targets and novel nonalcoholic steatohepatitis drugs: Pleiotropy assessed in the PheWAS United Kindom Biobank. Figure shows associations between gene variants in five nonalcoholic steatohepatitis-related molecular targets (*MAP3K5/ASK1*, *FXR*, *PPARα/δ*, *THRβ*, and *MPC1)* with different traits and phenotypes in the UK-PheWAS (Phenome-wide association study). Information regarding single nucleotide polymorphisms and associations were retrieved from the United Kindom Biobank (<http://geneatlas.roslin.ed.ac.uk/>).](WJG-25-1783-g005){#F5}

CONCLUSION
==========

We provide new strategies and approaches by which known drugs can be repurposed for the treatment of NASH. Although we explored and mapped NAFLD-chemical interaction networks, it will be necessary to perform clinical trials not only to assess therapeutic response and optimize dosage and delivery routes, but also to explore the possibility that new uses of existing (old) drugs could act on novel or unanticipated targets. The presence of potential "off target"-pleiotropic-effects raises the mandatory necessity of pharmacological optimization, including the assessment of drug interactions and adjustment according to liver function tests.
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